

(Fig. 1F) and desmin. These histologic and immunohistological results led to the diagnosis of NHH.

Additional pleural fluid had accumulated 3 weeks following the pleural biopsy (Fig. 1B). Dasatinib treatment was discontinued for 2 weeks, and an improvement of right pleural effusion was observed (Fig. 1C). No increase in the amount of pleural fluid was detected following the subsequent readministration of dasatinib.

To our knowledge, this is the first report of a case of dasatinib-related pleural effusion diagnosed as pleural NHH using both histological and immunohistological studies.

We identified dasatinib to be the cause of the pleural effusion, as the level of pleural fluids was found to be dependent upon dasatinib treatment. Furthermore, the analysis of the pleural fluid was in keeping with previous reports. Comorbidities, including cardiac diseases, renal insufficiency, hypertension, chronic obstructive pulmonary diseases, and lymphocytosis (>3600/ μ l) are risk factors for the occurrence of dasatinib-related pleural effusions.^{4,5} Lymphocytosis was detected in the current case.

The pathogenesis of dasatinib-related pleural effusion is unknown. Only 2 studies have used pleural biopsies to investigate the cause.^{6,7} Bergeron et al. detected the presence of lymphocytic or myeloid infiltration in the pleura,⁶ while Ustun et al. reported the presence of organizing fibrinous pleuritis.⁷ Therefore, the current report is the first to diagnose pleural NHH.

NHH is a benign proliferative process composed predominantly of histiocytes, which show immunoreactivity against CD68.^{8,9} NHH may be a reactive process caused by a variety of situations, such as mechanical irritation, inflammation, and tumor.¹⁰ In the present case, there was no history of previous surgery, and the CML was in the major molecular response phase. Furthermore, no primary or metastatic carcinomas were detected in the pleural effusion and biopsies studies. We therefore considered NHH to be a possible cause of dasatinib-related pleural effusion in this patient. It is, however, possible that the NHH was a secondary event resulting from adasatinib-related pleural effusion. Future studies implementing the use of pleural biopsy are thus essential to examine the cause of dasatinib-related pleural effusion.

The management of dasatinib-related pleural effusion includes therapeutic thoracentesis, temporary interruption of dasatinib (as described in this report), and a short course of prednisone.² Unfortunately, pleural effusion may be uncontrollable in a small percentage of dasatinib-treated patients.^{1,2} Further investigations are imperative to identify the mechanism underlying the development of pleural effusions to permit the optimal treatment of dasatinib-treated patients.

Acknowledgements

We thank Dr. Eiji Yamada for his comments regarding histopathologic findings.

References

- Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. *J Clin Oncol*. 2016;34:2333–40.
- Brixey AG, Light RW. Pleural effusions due to dasatinib. *Curr Opin Pulm Med*. 2010;16:351–6.
- de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. *Br J Haematol*. 2008;141:745–7.
- Paydas S. Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect. *Crit Rev Oncol Hematol*. 2014;89:242–7.
- Eskazan AE, Eyice D, Kurt EA, Elverdi T, Yalniz FF, Salihoglu A, et al. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. *Leuk Res*. 2014;38:781–7.
- Bergeron A, Réa D, Levy V, Picard C, Meignin V, Tamburini J, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. *Am J Respir Crit Care Med*. 2007;176:814–8.
- Ustun C, Randall N, Podgaetz E, Amin K, Dincer HE. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor. *Thorax*. 2015;70:701–4.
- Ordóñez NG, Ro JY, Ayala AG. Lesions described as nodular mesothelial hyperplasia are primarily composed of histiocytes. *Am J Surg Pathol*. 1998;22:285–92.
- Chikkamuniyappa S, Herrick J, Jagirdar JS. Nodular histiocytic/mesothelial hyperplasia: a potential pitfall. *Ann Diagn Pathol*. 2004;8:115–20.
- Chan JK, Loo KT, Yau BK, Lam SY. Nodular histiocytic/mesothelial hyperplasia: a lesion potentially mistaken for a neoplasm in transbronchial biopsy. *Am J Surg Pathol*. 1997;21:658–63.

Satoshi Hamada,^{a,*} Eiichi Hayashi,^b Mitsuhiro Tsukino^a

^a Department of Respiratory Medicine, Hikone Municipal Hospital, Hikone, Japan

^b Department of Thoracic Surgery, Hikone Municipal Hospital, Hikone, Japan

* Corresponding author.

E-mail address: sh1124@kuhp.kyoto-u.ac.jp (S. Hamada).

1579–2129/

© 2016 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Interstitial Lung Disease Caused by Oxaliplatin: An Uncommon But Not Unknown Complication[☆]



Enfermedad pulmonar intersticial secundaria a oxaliplatino. Una complicación infrecuente pero posible

To the Editor,

We report the case of a 62-year-old man with hypertension, diabetes, and dyslipidemia, heavy former smoker and chronic alcoholic, undergoing neurological monitoring for possible Wernicke–Korsakov syndrome. In December 2015, he was

diagnosed with locally advanced, high grade colorectal adenocarcinoma. After surgical intervention involving hemicolectomy, appendectomy, splenectomy, and omentectomy, the patient began FOLFOX adjuvant chemotherapy in January 2016, and received 8 cycles until April 2016, achieving stable disease on re-evaluation by computed tomography (CT). He presented in the emergency room 3 weeks after the last cycle of chemotherapy with dyspnea that had progressively worsened in the last week until it was experienced even at rest, with unproductive cough and 2 evening peaks of 38 °C temperature, which did not improve after 5 days of antibiotic treatment as an outpatient. Baseline saturation on arrival was 85%. Chest radiograph confirmed the existence of infiltrates consistent with bilateral bronchopneumonia and in line with the clinical and laboratory findings: C-reactive protein (CRP) 27 (0.1–0.5) and 20 000 leukocytes with left shift.

As the patient was immunocompromised (splenectomy, chemotherapy, alcoholism), wide spectrum antibiotics were

[☆] Please cite this article as: Cendra CS, Martel IJ, Abad DG. Enfermedad pulmonar intersticial secundaria a oxaliplatino. Una complicación infrecuente pero posible. *Arch Bronconeumol*. 2017;53:213–215.



Fig. 1. CT during admission, showing significant parenchymal involvement, compared to the previous normal CT, obtained one month previously at the end of the last chemotherapy cycle.

started with meropenem. Urine was antigen-negative and only 1 sputum sample could be obtained, which was sterile on culture. After 10 days of treatment the patient was afebrile, but pathological signs persisted on auscultation and he was dyspneic at rest, despite oxygen therapy. The follow-up chest radiograph revealed a new pulmonary infiltrate. On the assumption that antibiotic treatment had been ineffective and given the impossibility of obtaining another sputum sample due to the patient's unproductive cough, fiberoptic bronchoscopy was performed, but no microbiological isolates could be obtained from the samples collected. After this last test, the patient peaked fever again and his dyspnea deteriorated even further. His general condition was very poor, so a third chest radiograph was performed, showing worsening with respect to the image obtained 24 h previously. Treatment was intensified with vancomycin and cotrimoxazole, and the central venous access was withdrawn, in case it might have been an additional focus of infection. The patient was finally transferred to the ICU due to desaturation of around 75% despite high oxygen flow. Blood cultures obtained from the catheter and the peripheral access were both negative, as was culture of the catheter tip. The dyspnea study was completed with an echocardiogram, which was also normal. All serologies were negative, including HIV, hepatropic viruses, EBV, CMV, *Mycoplasma pneumoniae* and *Chlamydia pneumoniae*. CRP for CMV, influenza A/B Ag and galactomannan were also negative. No positive results were found in the autoimmunity study.

On follow-up blood tests, CRP values were seen to have plateaued at very low levels, but marked leukocytosis was observed despite the addition of antiviral and antifungal medication. Finally, a high-resolution chest CT (Fig. 1) revealed proliferative-fibrotic stage acute respiratory distress, traction bronchiectasis and bronchiolectectasis, and signs of loss of volume associated with very rapid fibrosis and extensive parenchymal involvement with areas suggestive of drug-related pneumonitis. Resistance to administered treatments, even in a final phase with high-dose corticosteroids, prompted orotracheal intubation, but even so the patient's respiratory situation deteriorated badly, and he finally died 5 weeks after admission.

Oxaliplatin is now widely used in chemotherapy regimens for colorectal cancer, and the combination of leucovorin-fluorouracil-oxaliplatin (FOLFOX) in particular has clearly shown efficacy in an adjuvant situation.¹ Some anticancer agents have been closely related with lung disease. For example, bleomycin showed a high

rate of mortality (The Drug-Induced Respiratory Disease Website: pneumotox), but the first studies performed to evaluate oxaliplatin toxicity did not initially show lung involvement as a side effect, and only a mild risk of hypersensitivity bronchospasm was reported. The main side effects are peripheral neuropathy and renal, hematological and gastrointestinal symptoms.² Now, several cases have been reported associating oxaliplatin with lung damage, but as these events have generally occurred in combination regimens, it is very difficult to establish the individual contribution of each drug. At least 1 case was published on the use of single-agent oxaliplatin in adjuvancy in 2005, in which only 1 previous cycle of 5FU had been administered,³ and more recently new publications on the FOLFOX scheme have appeared.⁴ According to the systematic review performed in a Japanese study of 734 patients with colorectal cancer treated with FOLFOX or FOLFIRI, 11 had interstitial pulmonary disease (1.5% compared to the 0.4% reported by the FDA for complications of this type with oxaliplatin).⁵ Mean time to appearance was 20 days after the last cycle, with a mean of 10 FOLFOX cycles and oxaliplatin dose of 85 mg/m².

This toxicity appears to be due to glutathione depletion (an antioxidant molecule), a hypothesis that was extrapolated from a study that demonstrated liver damage with oxaliplatin caused by perivascular and endothelial involvement.⁶

The most common clinical symptoms are cough and dyspnea, and fever is uncommon. Radiological findings usually include interstitial infiltrate and ground glass areas. Moreover, although histology is available in very few cases, the most common findings are diffuse alveolar damage and organizing pneumonia.⁷ Recommended treatment consists of support and high-dose systemic corticosteroids, but despite this, mortality is high.⁸

In conclusion, no clear evidence of oxaliplatin-induced lung toxicity is available beyond the cases reported, but that these suggest that not only is it a possibility, but that if it occurs, it can be so severe as to cause a fatal outcome, as we ourselves have witnessed. Arriving late at a definitive diagnosis, after all other possibilities are ruled out, complicates the situation further. The pre-existence of fibrosis or any other underlying disease will aggravate the situation even further,⁹ so great caution and close clinical and imaging follow-up must be employed when indicating oxaliplatin in this patients.

References

- Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Taberero J, Hickish T, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med.* 2004;350:2343-51.
- Ramanathan RK, Clark JW, Kemeny NE, Lenz HJ, Gococo KO, Haller DG, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. *J Clin Oncol.* 2003;21:2904-11.
- Yagüe XH, Soy E, Merino BQ, Puig J, Fabregat MB, Colomer R. Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. *Clin Transl Oncol.* 2005;7:515-7.
- Vargas A, Montironi C, Buxó E. Neumonía organizada con desenlace fatal tras quimioterapia adyuvante con FOLFOX. *Arch Bronconeumol.* 2015;51:610.
- Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. *Ann Oncol.* 2010;21:2005-10.
- Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. *Ann Oncol.* 2004;15:460-6.
- Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. *Open Respir Med J.* 2012;6:63-74.
- Garrido M, O'Brien A, González S, Clavero JM, Orellana E. Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. *Chest.* 2007;132:1997-9.
- Wilcox BE, Ryu JH, Kalra S. Exacerbation of preexisting interstitial lung disease after oxaliplatin therapy: a report of three cases. *Respir Med.* 2008;102:273-9.

Cristina Sánchez Cendra,* Ignacio Juez Martel, David Gutierrez Abad

Servicio de Oncología Médica, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain

* Corresponding author.

E-mail address: csanchez@salud.madrid.org (C.S. Cendra).

1579-2129/

© 2016 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Involvement of Mediastinal Lymph Nodes by Ewing's Sarcoma[☆]



Afectación adenopática mediastínica por sarcoma de Ewing

To the Editor,

We report the case of 20-year-old man with a history of Ewing's sarcoma in the left humerus diagnosed at the age of 15, who has been in medical oncological follow-up since then. After the diagnosis, he received 5 cycles of neoadjuvant VAC/ifosfamide-VP-16, followed by radical surgery, resulting in pathological complete response according to pathology reports. The patient completed 12 adjuvant cycles of the same regimen and proceeded to regular monitoring. After 2 years free of disease, he received a diagnosis of probable pleuro-pulmonary relapse on a PET-CT, which showed hypermetabolic foci in the oblique fissure of the right lung and in the right subcarinal and hilar lymph nodes, although the latter were described as probably of a non-specific inflammatory nature, and close monitoring with imaging techniques was recommended. No known drug allergies. No toxic habits or occupational exposure. Student; no significant family history. He was referred

by the medical oncology department to the respiratory medicine outpatient clinic due to the presence of mediastinal lymph nodes showing suspected tumor relapse on PET-CT. Clinical examination showed some degree of asthenia, but no other symptoms. Physical examination was normal. Clinical laboratory tests revealed completely normal serum biochemistry, complete blood count, and coagulation parameters. A computed tomography of the chest, abdomen and pelvis requested by the medical oncologist revealed a conglomerate lymph node mass in the subcarinal space, with bilateral hilar lymphadenopathies, and no other findings. Given these results, a PET-CT was requested, revealing the presence of hypermetabolic foci on the right lung and right subcarinal and pulmonary hilar lymphadenopathies, with higher metabolic intensity than the previous routine PET-CT (Fig. 1). Endobronchial ultrasound under anesthetist-controlled deep sedation was performed, revealing a rounded subcarinal lymph node mass measuring 12 mm with well-limited borders, homogeneous echostructure, and absence of central hilar structure or signs of necrosis. The lesion was aspirated 3 times for *in situ* cytopathology in the examination room, and enough material was obtained for subsequent studies. The pathological diagnosis was metastatic Ewing's sarcoma. After diagnosis, the patient received four chemotherapy cycles with the




Fig. 1. Hypermetabolic foci in subcarinal and right pulmonary hilar lymphadenopathies.

[☆] Please cite this article as: Caballero Vázquez A, García Flores P, Herrera Chilla Á. Afectación adenopática mediastínica por sarcoma de Ewing. Arch Bronconeumol. 2017;53:215–216.